Engflag

Becasone

Quick links to important sections

Becasone

Becasone_DA

Method of action: Antiallergic, Antiexudative, Anti-Inflammatory, Antiproliferative, Antipruritic, Corticosteroids For Systemic Use, Corticosteroids, Dermatological Preparations, Decongestant, Glucocorticoid, Immunosuppressive

Treatment option: Allergic Reactions, Allergic Conjunctivitis, Anemia, Ankylosing Spondylitis, Arthritis,Osteoarthritis, Asthma, Atopic Dermatitis, Autoimmune Hemolytic Anemia, Berylliosis, Plaque Psoriasis

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Becasone

Property Description
Active ingredient Betamethasone Dipropionate
Form Topical preparations (Cream, Ointment, Lotion, Gel)
Pharmacological class Corticosteroid / Glucocorticoid
Origin Synthetic

Becasone: Definition and Pharmacological Classification

Becasone is a prescription-only dermatological medication defined by its single active ingredient, Betamethasone Dipropionate (INN). This compound is classified as a potent synthetic adrenocorticosteroid and a glucocorticoid within the broader Corticosteroid pharmacological class.

As a potent agent, Betamethasone Dipropionate is a synthetic ester designed to target intense inflammation. This high potency is a key differentiating factor, making it suitable for managing stubborn, chronic skin conditions where milder steroids are insufficient. Pharmacological studies have clinically recognized its reliable efficacy for rapidly reducing severe symptoms in inflammatory skin conditions.

Composition, Origin, and Topical Forms

The medicine’s composition centers on the Betamethasone Dipropionate active ingredient combined with a specialized base/vehicle designed for topical delivery to the skin surface. Betamethasone Dipropionate is a synthetic compound, meaning it is chemically manufactured and not derived from natural sources.

This drug is manufactured in various physical dosage forms for dermatological use, typically including a cream, a heavier ointment, or a lighter lotion or gel. The choice of form allows the medicine to be tailored to the specific nature of the skin lesion; for example, the occlusive nature of the ointment form enhances absorption.

General Purpose and Anti-Inflammatory Principle

The general purpose of Becasone is to provide a powerful and targeted anti-inflammatory action and localized immunosuppressive action to the skin. This effect helps manage various inflammatory skin issues that are known to be responsive to the action of corticosteroids. These medications are used to relieve inflammatory symptoms and itching.

The medication achieves its therapeutic benefit by calming the immune system's overreaction in the affected tissue, thereby mitigating the core components of inflammation, ensuring a quick reduction of swelling, intense redness, and related symptoms such as profound itching (pruritus).

What side effects are possible with Becasone?

Possible Side Effects and Safety Information

The safety profile of Becasone, which contains the potent corticosteroid Betamethasone Dipropionate, is documented in official regulatory sources based on observed local and potential systemic effects. Adverse reactions are classified by frequency and the body system affected.

Local Skin and Subcutaneous Tissue Reactions

The most commonly reported adverse events are local, occurring at the application site. These include burning, stinging, and pruritus (itching), which are generally classified as common. Other local effects listed in regulatory documents include irritation, dryness, folliculitis, hypertrichosis (excessive hair growth), and changes to the skin structure such as skin atrophy (thinning), striae (stretch marks), and telangiectasias.

Potential for Systemic Safety Concerns

While uncommon, systemic absorption of the potent corticosteroid may lead to more serious effects, particularly with prolonged use or application over large surface areas. These serious adverse reactions relate primarily to the endocrine and metabolic systems and include the potential for reversible hypothalamic-pituitary-adrenal (HPA) axis suppression and manifestations consistent with Cushing's syndrome. Postmarketing surveillance has also noted the possibility of ophthalmic disorders, such as cataracts and glaucoma.

Population-Specific Safety Notes

Official labeling addresses specific populations, noting that pediatric patients may be more susceptible to systemic toxicity, including HPA axis suppression, due to their proportionally larger skin surface area to body weight ratio. Additionally, liver failure is recognized as a factor that may predispose an individual to HPA axis suppression. The medication is classified as Pregnancy Category C; animal studies showed teratogenic effects.

Overdose and Emergency Response

Overdose and when to seek help

The primary overdose risk associated with Becasone (Betamethasone Dipropionate Topical) is not from acute ingestion but from Systemic Absorption following prolonged or excessive use over large body surface areas. This excessive exposure can lead to the suppression of the body's natural hormone production, known as reversible Hypothalamic-Pituitary-Adrenal (HPA) axis suppression.

Documented manifestations of this systemic toxicity include clinical signs consistent with Cushing's syndrome, as well as laboratory findings such as Hyperglycemia and Glucosuria. Overdose may also lead to severe outcomes like Secondary Adrenal Insufficiency or, particularly in children, signs of Intracranial Hypertension.

Emergency Actions and When to Seek Help

Urgent medical assessment is required if any manifestations of systemic toxicity or symptoms of steroid withdrawal are observed. The officially documented management involves an attempt to withdraw the drug by reducing the frequency of application or substituting the treatment with a less potent corticosteroid. Periodic evaluation for HPA axis suppression is required using specific diagnostic tests. No specific antidote is known for this overdose scenario.

Population-Specific Note

Pediatric patients are more susceptible to systemic toxicity due to their higher skin surface-to-body mass ratio. Specific signs of adrenal suppression in children include linear growth retardation and delayed weight gain.

Therapeutic Uses of Becasone

What Becasone Treats: Main Uses and Benefits

Becasone (Betamethasone Dipropionate) is generally a topical medication applied across therapeutic domains where supportive symptom management is appropriate for skin conditions presenting with significant inflammation and irritation. It is applied in addressing symptoms related to physical discomfort, such as itching, redness, dryness, crusting, scaling, inflammation, and discomfort of various skin conditions. It is relevant when temporary assistance in symptom stabilization is appropriate to **ease the overall burden of distressing manifestations.

Addressing Severe Inflammatory Dermatoses

This medication is relevant in conditions characterized by periods of heightened symptoms, which may include plaque psoriasis, atopic dermatitis (eczema), and other related dermatoses. It is applied in clinical settings that involve acute or unstable symptom patterns where additional symptomatic support is needed. Becasone may assist with addressing symptoms linked to inflammatory or irritative states.

“It is commonly used across conditions presenting with acute episodes where short-term symptomatic assistance is needed.”

Providing Support for Intense Itching and Swelling

Becasone helps manage symptom clusters that may become intense or disruptive. It is applied in addressing symptoms related to physical discomfort, such as intense itching (pruritus), redness (erythema), and localized swelling. Applied during phases when symptoms become more noticeable, it contributes to easing the overall symptom load during periods of heightened symptoms and supports patients during difficult episodes by easing distress.

Quick Fact: Management of Pruritic & Inflammatory Symptoms Becasone is commonly used to help with symptoms that interfere with daily comfort, addressing symptom clusters such as itching, swelling, and redness.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Beclomethasone — Official Regulatory Information

Beclomethasone (often referred to by the active substance name) is an inhaled or intranasal corticosteroid for maintenance treatment. The official regulatory documents strictly define the populations who must not use the medicine.

Populations Who Must Not Use Beclomethasone (Contraindications):

  • Patients with a known hypersensitivity or allergy to beclomethasone dipropionate or any other ingredient in the specific product formulation.
  • Patients in the primary treatment of status asthmaticus or other acute episodes of asthma where intensive, rapid measures are required. This medicine is not a rescue inhaler for acute breathing difficulty.
Classification Eligibility Status Special Considerations
Age Limits Use is not established for very young children (e.g., typically under 4, 5, or 6 years old depending on the specific product and route of administration). For geriatric patients, caution is advised due to the potential for age-related conditions.
Infection/Clinical State Use requires caution in patients with pre-existing or non-immune status for infections, such as tuberculosis, fungal, bacterial, viral, or parasitic infections, or ocular herpes simplex. Intranasal formulations should be avoided until healing occurs in patients with recent nasal surgery, trauma, or septal ulcers.

These constraints ensure the medicine is used only as a prophylactic therapy by the approved populations, based on documented safety and efficacy findings.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation for Becasone (Betamethasone Dipropionate topical) defines its interaction profile primarily by the risk of additive pharmacodynamic effects, rather than specific metabolic interactions typically observed with systemically absorbed drugs.

Documented Interaction Profile

Detail Official Regulatory Statement
Interacting Product Class Other Corticosteroid-Containing Products (topical or systemic).
Mechanistic Basis Pharmacodynamic (PD) Additive Risk. Co-administration increases the cumulative potential for systemic corticosteroid effects, such as HPA axis suppression.
Timing-Based Rules None documented. Regulatory text does not specify mandatory time separation for administration.
Metabolic Interactions None known/documented. Formal drug-drug interaction studies related to CYP enzymes were not conducted for the topical formulation.

Population-Specific Considerations

Regulatory labeling notes that certain conditions may increase the potential for systemic exposure and related additive effects:

  • Hepatic Impairment: Patients with impaired liver function are at increased risk of systemic exposure due to potential reduced clearance.
  • Pediatric Patients: This population is documented to be more susceptible to systemic toxicity, which increases the clinical relevance of any additive pharmacodynamic risk.

No formal interactions with food, alcohol, herbal products, or supplements are documented in the official prescribing information for this topical medication. No specific medicinal products are listed as formally contraindicated for co-administration.

Mechanism of Action

How Becasone Works

The action of Betamethasone Dipropionate begins at the cellular level by acting as an agonist with high receptor affinity for the Glucocorticoid Receptor (GR). The ensuing mechanism is two-fold, involving deep genomic regulation and local vascular control to modulate the inflammatory cascade.

Genomic Regulation of Inflammatory Genes

This mechanism involves the drug-receptor complex entering the cell nucleus to directly influence gene expression. By increasing the production of anti-inflammatory proteins (transactivation) and blocking the function of pro-inflammatory transcription factors like NF-kappaB (transrepression), the drug fundamentally changes the cell's output. This action suppresses the synthesis and release of key signaling molecules—such as prostaglandins, leukotrienes, and cytokines—which are pro-inflammatory signaling molecules.

Local Vascular and Physiological Dampening

The combined genomic actions and a direct local effect on blood vessels influence the inflammatory cascade at a tissue level. The drug indirectly inhibits the enzyme Phospholipase A2 (PLA2), blocking the precursor to inflammatory mediators. Simultaneously, it induces vasoconstriction (narrowing of local blood vessels) and decreases capillary permeability. These physiological changes restrict blood flow and fluid leakage into the affected tissue, resulting in decreased interstitial fluid accumulation and reduced erythema.

Dosage and Administration Information

How to Use Becasone: Official Administration Guidelines

Becasone (Betamethasone Dipropionate) is a potent synthetic corticosteroid available in various topical preparations, including cream, ointment, lotion, and gel. The medicine is strictly for external use only and its application is governed by specific standards to limit systemic exposure.

Official Usage Parameters

Instruction Category Official Guideline (Label-Based)
Administration Route Topical (applied to the skin surface only).
Dosing Quantity Apply a thin layer sufficient to cover the affected area.
Maximum Weekly Dose Generally not to exceed 45 grams per week in adults.
Frequency Typically once or twice daily, depending on the formulation and condition.
Duration Constraint Continuous use is generally limited to 14 consecutive days for many conditions.

Procedural and Anatomical Constraints

The usage protocol emphasizes controlled application. The medication should not be used on the face, groin, or axillae (armpits) unless specifically directed by a healthcare professional. Furthermore, the treated area must not be bandaged or otherwise covered (occluded), as this can substantially increase absorption.

For pediatric use, the guidelines require the smallest amount possible and the shortest duration necessary due to the higher potential for systemic absorption in children. Treatment should be discontinued promptly once the condition is under control.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research on Primary Use in Type II Diabetes

Research has explored the use of the drug in treating adult-onset Type II diabetes. Studies examined the drug's profile when used in adult participants with Type II diabetes.

  • Glycemic Control: Research examined A1C levels as an endpoint, and changes in blood glucose levels were observed in study participants.
  • Intended Action: Research has explored the drug's intended action.
  • Secondary Observations: Research investigated appetite changes and documented patient reports of fatigue.

Combination Therapy: Studies on Co-administration

Studies have investigated the use of the drug in combination with other treatments for Type II diabetes.

  • Co-administration with Metformin: Research explored whether co-administration with metformin impacted endpoints related to cardiovascular events. Trial data included documentation of adverse events in adult study participants.
  • Studies with Other Agents: Other trials investigated the drug’s use alongside sulfonylureas and basal insulin.

Long-Term Research and Safety Profile

Clinical research has tracked the long-term findings related to the drug in participants with Type II diabetes.

  • Outcomes: Long-term studies tracked patient outcomes over five years.
  • Side Effects: Clinical trials data indicated that the most frequently observed adverse events involved gastrointestinal issues (nausea, diarrhea) and injection site reactions.

How should Becasone be stored and disposed of?

Storage and Disposal Requirements for Becasone

Becasone (Betamethasone Dipropionate topical) must be stored strictly according to regulatory standards to maintain its stability.

Storage Conditions

Storage Requirement Official Condition
Temperature Store at controlled room temperature, typically 20 C to 25 C. Do not freeze or expose to temperatures above 30 C.
Container Keep in the original container with the closure tightly closed when not in use.
Environment Protect the medicine from moisture and excessive heat.
Safety Keep the medicine out of the sight and reach of children at all times.

Disposal Instructions

Expired or unused Becasone should be discarded as directed by local regulations. Do not flush the medicine down a toilet or pour it down a drain. Utilize authorized drug take-back programs where available for proper pharmaceutical disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagTaiwan

Equivalent of Becasone found in:

A-Z Index: